blogged find better blogs
HomeTechnologyEntertainmentSportsPoliticsBusinessHumorWorld NewsLifestyleDirectoryMore Topics
Blog Detail
Stock Blog Hub

a VitalStocks Blog Setup.
Stock Blog Hub  
Related Blogs
previous blog next blog
6.5
good
based on editor's review


recent postsrss feed

Allos TherapeuticsAwaits FDA Report on Folotyn

Sep 24, 2009
We are awaiting the US Food and Drug Administration’s (FDA) decision regarding Allos Therapeutics’ (ALTH) lymphoma drug Folotyn. The company, which is seeking approval of Folotyn for the treatment of relapsed or refractory peripheral T-Cell lymph...

(GPS) Specialty Retailer Gap's Earnings Improve

Nov 20, 2009
Gap Inc. (GPS), a premier international specialty retailer, has reported healthy third quarter results despite challenging market conditions. The company reported net income of $307 million or 44 cents per share during the quarter compared to $246...

(CYBX) Cyberonics Beats Expectations – Raises Outlook

Nov 20, 2009
Cyberonics, Inc. (CYBX) reported second quarter fiscal 2010 earnings per share of 32 cents, beating the Zacks Consensus Estimate of 20 cents and the year-ago earnings of 14 cents. Sales Net sales in the reported quarter increased 13.0% year over year...

(LTD) Limited Brands Raises Guidance

Nov 20, 2009
Limited Brands Inc. (LTD) reported results for the third quarter of fiscal 2009 with earnings of 2 cents per share. Earnings were below the Zacks Consensus Estimate of 6 cents but were up 50% compared to the prior-year quarter. Net sales for the...

(ADCT) ADC Telecommunications Dips on Weak Outlook

Nov 20, 2009
Yesterday, after market close, ADC Telecommunications Inc. (ADCT) declared financial results for the fourth quarter of fiscal 2009. Earlier, the Board of Directors of ADC had taken a decision to change its fiscal year from Oct 31 to Sep 30. As a...

(GME) GameStop Corporation Meets Expectations

Nov 20, 2009
GameStop Corporation (GME) the biggest video game retailer, reported third quarter earnings of 32 cents per share, slightly above the Zacks Consensus Estimate of 31 cents. The reported earnings were 6% lower than prior-year quarter. Revenue for the...

Allos TherapeuticsAwaits FDA Report on Folotyn



Comments & Reviews:
Be the First to Review this Blog!